Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273374 | 0.93 | MAPT (0.47) | MAPTPKMMAPK1ALDH1A1TDP1 | |
| SCHEMBL310903 | 0.86 | MAPT (0.45) | MAPTPKMMAPK1ALDH1A1TDP1 | |
| SCHEMBL25427390 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1TDP1KDM4ECYP3A4 | |
| SCHEMBL228990 | 0.85 | ALDH1A1 (0.58) | MAPTPKMMAPK1ALDH1A1TDP1 | |
| SCHEMBL6371735 | 0.84 | ALDH1A1 (0.48) | MAPTALDH1A1TDP1KDM4ECYP3A4 | |
| SCHEMBL30230904 | 0.84 | ALDH1A1 (0.48) | MAPTPKMMAPK1ALDH1A1TDP1 | |
| SCHEMBL4279356 | 0.84 | ALDH1A1 (0.48) | MAPTPKMMAPK1ALDH1A1TDP1 | |
| SCHEMBL30954094 | 0.84 | ALDH1A1 (0.48) | MAPTALDH1A1TDP1KDM4ECYP3A4 | |
| SCHEMBL6117320 | 0.81 | ALDH1A1 (0.46) | MAPTMAPK1ALDH1A1TDP1KDM4E | |
| SCHEMBL17038146 | 0.81 | CYP1A2 (0.49) | MAPTPKMMAPK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-7230011-B2 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht6 receptor | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1377580-B1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | FILLA SANDRA ANN (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1377580-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002060871-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | HTR6, HTR5A, TPH1 | MAPT 3887/4885PKM 4017/4885MAPK1 1555/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | MAPT 3701/4885PKM 3346/4885MAPK1 2731/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAPT 3701/4885PKM 3346/4885MAPK1 2731/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAPT 3701/4885PKM 3346/4885MAPK1 2731/4885 |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR5A, HTR7 | MAPT 3743/4885PKM 3758/4885MAPK1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.